Abstract
To evaluate the impact of actinic keratosis (AK) and the effect of four AK treatments on the health-related quality of life (HRQoL), the Skindex-29 and AKQoL questionnaires were completed by 624 patients with AK participating in a randomized controlled trial (RCT) comparing 5% fluorouracil-cream, 5% imiquimod-cream, methyl-aminolevulinate photodynamic therapy (MAL-PDT), and 0.015% ingenol mebutate gel. Patients completed the questionnaires at baseline and 12 months post-treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
